Skip to main content

Tag: Alzheimer’s disease

Research Agreement Signed with Cerveau Technologies

Cerveau Technologies Inc. signed an agreement with the MGH Gordon Center to support multiple projects over the next several years. These research projects are for studies of an early stage imaging agent (MK-6240) to be used in Positron Emission Tomography (PET) scans for assessing the status and progression of neurofibrillary tangles (NFTs) in the brain. NFTs made up of aggregated tau protein are a hallmark of several neurodegenerative diseases, including Alzheimer’s disease.

2017 Gordon Science Symposium Featuring Dr. Rudolph Tanzi

Dr. Rudolph Tanzi is a Professor of Neurology at Harvard Medical School and and the Director of the Genetics and Aging Research Unit at Massachusetts General Hospital (MGH). He co-discovered three of the first Alzheimer’s disease genes and has identified several others in the Alzheimer’s Genome Project, which he directs. Dr. Tanzi was the keynote […]

Post-Translational Modifications and Age-Related Diseases

Dr. Tae Ho Lee is Assistant Professor of Medicine at Harvard Medical School. He was the guest speaker at a lecture organized by the MGH Gordon Center. Below is his presentation summary. Phosphorylation of proteins is one of the most important post-translational modifications (PTMs) and a key signaling mechanism in diverse physiological and pathological processes. Its deregulation contributes […]

Tau PET Imaging in Drug Development – Dr. Eric Hostetler

Tau proteins (named after the Greek letter T) are commonly associated with chronic neurodegenerative diseases such as Alzheimer’s disease (AD) and traumatic brain injuries. Positron Emission Tomography (PET), a non-invasive imaging technology, is used to measure disruptive tau accumulations in the brain. Currently there are few available PET tracers that can be used to measure […]